Ras Protein and Pancreas Cancer
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
== Disease == | == Disease == | ||
The absence of, or mutations of these proteins cause major diseases, cancers in lungs, bladder, pancreas, and heart are the most common but not the only ones. These proteins are very important for everything because they control a lot of functions in cells. The absence of, or mutations of these signaling proteins can cause terrible damage to our body. The gene KRas which produces the KRas protein, this protein participates in cellular signaling, it controls the growth and death of cells. The normal form of this protein is natural KRas but when it gets mutated, different types of cancer can be found such as lung, colorectal and pancreas. Having these changes (mutations) might have a possible stimulation in the cells’ growth causing this the spreading of the cells in the body. Is key to verify if the tumor has the shape of a mutated or natural KRas gene so that the treatment of the cancer can be planified. | The absence of, or mutations of these proteins cause major diseases, cancers in lungs, bladder, pancreas, and heart are the most common but not the only ones. These proteins are very important for everything because they control a lot of functions in cells. The absence of, or mutations of these signaling proteins can cause terrible damage to our body. The gene KRas which produces the KRas protein, this protein participates in cellular signaling, it controls the growth and death of cells. The normal form of this protein is natural KRas but when it gets mutated, different types of cancer can be found such as lung, colorectal and pancreas. Having these changes (mutations) might have a possible stimulation in the cells’ growth causing this the spreading of the cells in the body. Is key to verify if the tumor has the shape of a mutated or natural KRas gene so that the treatment of the cancer can be planified. | ||
- | The RAS family of small GTPases includes three genes: HRAS, NRAS, and KRAS. Each RAS protein is comprised of two major domains, the G domain and the membrane targeting domain | + | The RAS family of small GTPases includes three genes: HRAS, NRAS, and KRAS. Each RAS protein is comprised of two major domains, the G domain and the membrane targeting domain <ref name='Daniel'>PMID: 27096871</ref>. All of the isoforms are similar in the amino acid sequence of the G domain with major differences being restricted to the hypervariable region of their C-terminal domains. Mutations in RAS occur in residues 12, 13 and 61, and inhibit GTP hydrolysis activity (Daniel ZeitouniOrcID, 2016). The three RAS genes constitute the most frequently mutated oncogene family in human cancers; however, the specific isoform and amino acid mutation |
- | + | ||
varies among cancers (Daniel ZeitouniOrcID, 2016). Mutations in HRAS are most | varies among cancers (Daniel ZeitouniOrcID, 2016). Mutations in HRAS are most | ||
frequently found in melanoma, bladder and mammary carcinoma; NRAS mutations are found in melanoma and thyroid carcinoma; and KRAS mutations are most prevalent in | frequently found in melanoma, bladder and mammary carcinoma; NRAS mutations are found in melanoma and thyroid carcinoma; and KRAS mutations are most prevalent in |
Revision as of 15:16, 1 May 2019
Your Heading Here (maybe something like 'Structure')
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Mueller MP, Goody RS. Review: Ras GTPases and myosin: Qualitative conservation and quantitative diversification in signal and energy transduction. Biopolymers. 2016 Aug;105(8):422-30. doi: 10.1002/bip.22840. PMID:27018658 doi:http://dx.doi.org/10.1002/bip.22840
- ↑ Mueller MP, Goody RS. Review: Ras GTPases and myosin: Qualitative conservation and quantitative diversification in signal and energy transduction. Biopolymers. 2016 Aug;105(8):422-30. doi: 10.1002/bip.22840. PMID:27018658 doi:http://dx.doi.org/10.1002/bip.22840
- ↑ Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science. 1991 May 10;252(5007):802-8. PMID:1902986
- ↑ Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016 Apr 18;8(4). pii: cancers8040045. doi:, 10.3390/cancers8040045. PMID:27096871 doi:http://dx.doi.org/10.3390/cancers8040045